EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers

Jaeyop Lee, Geoffrey Ku

Hematology/Oncology Clinics of North America · 2024

DOI: 10.1016/j.hoc.2024.02.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology/Oncology Clinics of North America, 2024. Verfasst von Jaeyop Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Molecular Targeted Therapy, Immunoconjugates. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Trastuzumab for Gastric Cancer (ToGA) trial marked a pivotal moment in the adoption of trastuzumab for treating advanced human epidermal growth factor receptor 2 (HER2)-positive esophagogastric (EG) cancer. The KEYNOTE-811 trial brought to light the synergistic effect of immune modulation and HER2 targeting. Additionally, the emergence of trastuzumab deruxtecan (T-DXd) highlighted the potential of new pharmaceutical technologies to extend response, particularly for patients who have advanced beyond initial HER2-targeted therapies. This review aims to navigate through both the successes and challenges encountered historically, as well as promising current trials on innovative and transformative therapeutic strategies, including promising first-in-class and novel first-in-human agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesMolecular Targeted TherapyImmunoconjugatesHumansGastrointestinal NeoplasmsTrastuzumabStomach NeoplasmsAntineoplastic Agents, ImmunologicalClinical Trials as TopicCamptothecin

Stichwörter der Autor:innen

Antibody drug conjugateEsophagogastric cancerHER2Immune modulationImmunotherapyTargeted therapyTrastuzumab

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabAntineoplastic Agents, ImmunologicalCamptothecinImmunoconjugatesERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: kug@mskcc.org.

Zitieren

APA

Lee, J., & Ku, G. (2024). Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers. Hematology/Oncology Clinics of North America. https://doi.org/10.1016/j.hoc.2024.02.005

Vancouver

Lee J, Ku G. Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers. Hematology/Oncology Clinics of North America. 2024. doi:10.1016/j.hoc.2024.02.005

BibTeX
@article{Lee2024,
  author = {Lee, Jaeyop and Ku, Geoffrey},
  title = {Advances in Human Epidermal Growth Factor Receptor 2-Targeted Therapy in Upper Gastrointestinal Cancers},
  journal = {Hematology/Oncology Clinics of North America},
  year = {2024},
  doi = {10.1016/j.hoc.2024.02.005}
}
Kostenlos starten →